Owning to a variety of relevant reasons, which include trypanophobia and dependence on the cold chain, there is an evident demand for innovative and user-friendly vaccine delivery systems that are also safe and efficient
With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism.In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.
To order this detailed 500+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape featuring over 280 stem cell-based therapies approved / under clinical development, including information on drug / therapy developer(s) (such as year of establishment,
The potential therapeutic applications of RNAi were realized almost immediately after the phenomenon was first described; over the years, developers have gradually progressed their proprietary drug candidates with cautious optimism
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years. Further, recent studies suggest that mesenchymal stem cells mesenchymal stem cells can be effectively used to improve patients' resistance to the SARS-CoV-2 virus induced pneumonia leading to speedy
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon ... Read more
Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment
To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this
Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment
To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this ... Read more
Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
To order this 330+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters),
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are ... Read more
STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy and is being pursued by several large pharmaceutical companies
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
To order this 330+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of
Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.
To order this 480+ page report, which features 350+ figures and 260+ tables, please visit
